Stryker (SYK) exceeded Q3 2025 expectations, reporting revenue of $6.06 billion, a 10.3% year-over-year increase, and EPS of $3.19, surpassing consensus estimates by 0.24% and 1.59% respectively. Key drivers included robust 11.2% growth in U.S. sales and an 18% surge in the MedSurg and Neurotechnology segment, despite a slight 0.7% year-over-year decline in overall Orthopaedics sales which still beat estimates. The company's shares have underperformed the broader S&P 500 over the last month, currently holding a Zacks Rank #3 (Hold).
Stryker (SYK) reported robust Q3 2025 results, with revenue reaching $6.06 billion, a 10.3% year-over-year increase, and EPS of $3.19. These figures surpassed Zacks Consensus Estimates by 0.24% for revenue and 1.59% for EPS, indicating solid operational execution and strong headline performance. Key growth drivers included a significant 11.2% year-over-year increase in U.S. sales to $4.57 billion, exceeding estimates, and an impressive 18% surge in the MedSurg and Neurotechnology segment. While overall Orthopaedics sales experienced a marginal 0.7% year-over-year decline, the segment's $2.25 billion still surpassed analyst estimates, notably supported by a strong 59.8% growth in Orthopaedics-Other. Despite the positive earnings surprise, SYK shares returned only +0.7% over the past month, underperforming the S&P 500's +2.1% gain. The stock's current Zacks Rank #3 (Hold) suggests that analysts anticipate near-term performance to align with the broader market, potentially reflecting a balanced view of the strong headline numbers against mixed segment-level performance.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.65
Ticker Sentiment
